Abrocitinib: First Approval

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

(2021) Jonathan I. Silverberg et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis

(2021) Eric L. Simpson et al.   Dermatitis

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

(2021) Ellen Q. Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

(2021) Thomas Bieber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

(2021) Eric L. Simpson et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement

(2021) Brian S. Kim et al.   Dermatitis

27590 Abrocitinib in the treatment of moderate-to-severe atopic dermatitis refractory to dupilumab treatment: An analysis of JADE-EXTEND, a phase 3 long-term extension study

(2021) Vivian Shi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis

(2021) Lawrence F. Eichenfield et al.   JAMA Dermatology

Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib

(2020) Sandra Ferreira et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

(2019) Melinda J. Gooderham et al.   JAMA Dermatology

Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study

(2018) Elena Peeva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

(2018) Michael L. Vazquez et al.   JOURNAL OF MEDICINAL CHEMISTRY

JAK Inhibitors for Atopic Dermatitis: An Update

(2018) Helen He et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY